High-Risk Localized and Locally Advanced Prostate Cancer
Around 20%-30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of "high-risk" may need to be validated first. Although recent advances in radiotherapy for...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Around 20%-30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of "high-risk" may need to be validated first. Although recent advances in radiotherapy for prostate cancer have yielded excellent long-term results, even in high-risk localized disease, there are no studies directly comparing it with local treatment options, such as prostatectomy. To address current challenges in high-risk localized and locally advanced prostate cancer, 12 original and 3 review articles covering aspects from basic research to clinical trials are published in this Special Issue. |
---|---|
Physical Description: | 1 electronic resource (244 p.) |
ISBN: | books978-3-0365-8169-9 9783036581682 9783036581699 |
Access: | Open Access |